The Landscape of Immunotherapy for Retroperitoneal Sarcoma

Authors

Alicia A Gingrich
Elise F Nassif
Christina L Roland
Emily Z Keung

Publication Date

2-9-2023

Journal

Current Oncology

Abstract

Significant multidisciplinary scientific effort has been undertaken to understand the heterogeneous family of neoplasms that comprise soft tissue sarcomas. Within this family of neoplasms, outcomes for retroperitoneal sarcomas (RPS) are currently limited given a lack of effective therapies. In this review, we focus on immunotherapy and its relationship with the common RPS histologic subtypes. Although initial outcomes for RPS patients with immune checkpoint inhibition alone have been somewhat disappointing, subsequent analyses on histologies, the tumor microenvironment, sarcoma immune class, tumor infiltrating lymphocytes and genetic analysis for tumor mutational burden have yielded insight into the interplay between sarcomas and immunotherapy. Such approaches have all provided critical insight into the environment and characterization of these tumors, with targets for potential immunotherapy in future clinical trials. With this insight, molecularly tailored combination treatments for improving response rates and oncologic outcomes for RPS are promising.

Keywords

retroperitoneal sarcoma, immunotherapy, sarcoma immune class, tumor microenvironment, tumor infiltrating lymphocyte, tumor mutational burden

Comments

PMID: 36826126